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Abstract
Congenital analbuminemia is an autosomal recessive disorder, in which albumin, the major blood protein, is present only in a minute amount. The 
condition is a rare allelic heterogeneous defect, only about seventy cases have been reported worldwide. To date, more than twenty different muta-
tions within the albumin gene have been found to cause the trait. In our continuing study of the molecular genetics of congenital analbuminemia, 
we report here the clinical and biochemical findings and the mutation analysis of the gene in two Turkish infants. For the molecular analysis, we 
used our strategy, based on the screening of the gene by single-strand conformation polymorphism, heteroduplex analysis and direct DNA sequen-
cing. The results showed that both patients are homozygous for the deletion of a cytosine residue in exon 5, in a stretch of four cytosines starting 
from nucleotide position 524 and ending at position 527 (NM_000477.5(ALB):c.527delC). The subsequent frame-shift inserts a stop codon in position 
215, markedly reducing the size of the predicted protein product. The parents are both heterozygous for the same mutation, for which we propose 
the name Erzurum from the city of origin of the family. In conclusion, our results show that in this family congenital analbuminemia is caused by 
a novel frame-shift/deletion defect, confirm the inheritance of the trait, and contribute to advance our understanding of the molecular basis un-
derlying this condition. 
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Case report
Introduction
Human albumin (ALB; UniProt ID: P02768) repre-
sents just less than two-thirds of total serum pro-
teins (1) and is encoded by a single gene (ALB; 
GenBank accession no. NC_000004.11), mapping 
at chromosome 4q13.3, which consists of 15 exons 
(2). Homozygous or compound heterozygous mu-
tations in this gene have been associated with 
congenital analbuminemia (CAA, OMIM 103600), 
which results in a significant reduction of the pro-
tein in the blood. Heterozygous, or in very rare 
cases, homozygous mutations may also lead to a 
circulating genetic variant of ALB (bisalbuminemia 
or alloalbuminemia, OMIM 103600) (3), which, with 
a few exceptions, do not seem to have clinical rel-
evance (4). 
Usually, the clinical diagnosis of CAA is based on 
routine or capillary serum protein electrophoresis, 
which shows a marked reduction of the ALB con-
centration and a compensatory increase of the 
other protein fractions (3,5,6). Of course, physi-
cians should rule out the presence of other more 
common causes which can lower the concentra-
tion of circulating ALB, such as gastrointestinal or 
renal losses, redistribution into extra-vascular 
compartments and hepatic dysfunction (3,5-7). In 
contrast to the first studies on this topic, which de-
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fined as “true” analbuminemic subjects only indi-
viduals with an ALB concentration < 1 g/L, we have 
more recently described several cases character-
ized by ALB concentrations around 10 g/L (7-11). 
Probably, an overestimation of the real ALB con-
centration at this low levels by serum protein elec-
trophoresis or by dye-binding bromcresol green 
reagents (12) may explain this apparent discrepan-
cy. A useful clue to the clinical diagnosis is the 
presence in the parents of the affected individuals 
of ALB concentrations significantly lower than nor-
mal. In fact, CAA occurs in homozygous or com-
pound heterozygous individuals and heterozy-
gous carriers, due to the presence of only one nor-
mal allele, usually show ALB concentrations close 
to the lower limit of the normal range (1,3,5,6). 
The main clinical symptoms in adult analbumine-
mic individuals are oedema, hypotension, fatigue 
and, mainly in adult females, lower-body lipodys-
trophy (1,3,5,6). These symptoms seem relatively 
mild with respect to the many and important roles 
of ALB, but its low concentration can be partially 
compensated for by an increase in the synthesis of 
other serum proteins (1,3,5,6). The most common 
biochemical sign is a marked alteration of the lipid 
profile, with hypercholesterolemia and elevated 
LDL cholesterol levels (1,3,5,6), which may have 
been responsible for some cases of premature cor-
onary heart disease (13). Although the absence of 
a follow-up in most cases makes it difficult to draw 
conclusions on this point, several authors have 
recommended treatment with statins (14).
The condition is very rare: only about seventy cas-
es have been so far reported world-wide and are 
listed in the Register of Analbuminemia Cases (15). 
However, the prevalence of the causative muta-
tions at the heterozygous state is probably some-
what higher than hitherto believed (less than 
1:1.000.000), since the most common among 
them, Kayseri (c228_229delAT), has an allele fre-
quency of about 6:100.000 (16). This condition is 
rare also in consideration that CAA may be a risk 
factor during the perinatal and the childhood pe-
riod (17-19). In fact, foetal or neonatal death of sib-
lings has been frequently observed in the families 
of analbuminemic subjects, pointing to the crucial 
role of ALB in fetal development (3,5,6).
The clinical diagnosis of CAA needs to be con-
firmed by screening methods of the ALB aimed at 
the identification of the defect causing the lack of 
the protein. This is mandatory in order to differen-
tiate from other secondary causes of hypoalbu-
minemia and for the genetic counselling of the 
family. In our continuing study of the molecular 
basis of CAA, we describe here the clinical and bio-
chemical findings in two analbuminemic Turkish 
children together with the screening for mutations 
of the ALB in their family.
Materials and methods
Subjects 
We observed at the Kanuni Sultan Suleyman Re-
search and Training Hospital, Istanbul, Turkey a 
consanguineous (first degree cousins) family com-
posed by four offspring from Erzurum, East Anato-
lia, Turkey. The clinical and biochemical studies 
were performed from 2013 to 2015. The mother 
was 27 and the father was 32 years old, and they 
were both apparently healthy. They have four kids 
from three pregnancies, two of which are the in-
dex cases. The procedures were in accordance 
with the latest version of the Declaration of Helsin-
ki. We collected blood samples after obtaining 
signed informed consent from all participants in-
volved in the study. For the four kids the consent 
was signed by the parents. The molecular analysis 
was carried out in 2015 at the Department of Mo-
lecular Medicine, University of Pavia, Pavia, Italy 
and at Laboratory on Pathophysiology of Uremia, 
Istituto Giannina Gaslini IRCCS, Genova, Italy. 
Methods
Serum ALB concentration was quantified by a 
modified bromcresol purple-binding assay in a Di-
mension® EXL™ 200 Integrated Chemistry System 
(Siemens Healthcare GmbH, Erlangen, Germany). 
Serum protein electrophoresis was performed by 
the fully-automated V8 Capillary Electrophoresis 
System (Helena Biosciences Europe, Gateshead, 
UK), designed to optimise and completely auto-
mate electrophoresis testing. Other analytes were 
assayed by conventional techniques using a fully-
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automated ADVIA® 1800 Clinical Chemistry System 
(Siemens Healthcare GmbH, Erlangen, Germany). 
Mutation analysis
DNA was isolated from EDTA-treated whole blood 
and sent to Pavia by a Next Day Parcel Delivery. 
PCR amplification of the 14 segments containing 
exons and flanking regions of the ALB gene (2) was 
performed using specific set of primers as de-
scribed by Watkins et al. (18) and the conditions re-
ported by Caridi et al. (8). Single strand conforma-
tion polymorphism (SSCP) heteroduplex analysis 
(HA), and the preparation of PCR products for se-
quence analysis were performed essentially as 
previously described (8,11,20). Samples were sub-
jected to automated DNA sequencing on an Ap-
plied Biosystems™ 3100 xl instrument (Thermo 
Fisher Scientific, Milano, Italy), and analyzed by Se-
quencer software (5.0 version, Gene Code Corpo-
ration, Ann Arbour MI, USA).
Case description
Six members compose the family we studied in 
the present paper. The parents, who are first-de-
gree cousins, have four kids from 3 pregnancies, 
two of which affected by CAA (Figure 1). There is 
no history of miscarriage or fetal death. 
Sibling 1: The elder patient is a female, who is now 
two and half years old (sibling 1 in Figure 1). She 
was born at 29th week of gestation, from an in vit-
ro fertilization induced twin pregnancy. Her twin 
brother is healthy. Her birth weight was 1150 g. 
She stayed for 50 days at neonatal intensive care 
unit (NICU) because of premature birth and respir-
atory distress, but the follow-up revealed no histo-
ry of this problem or of frequent infections. During 
that period, she had seizures and received anti-ep-
ileptic drugs. One year ago her electroencepha-
lography was repeated and the anti-epileptic ther-
apy was stopped. Her renal ultrasonography and 
calcium excretion were normal, but the blood cal-
cium levels were always low and she consumed vi-
tamin D and calcium supplementation, until her 
blood vitamin D became too high due to excessive 
addition. She was diagnosed with hypothyroidism 
during neonatal period, and since then she re-
ceives thyroid hormone replacement therapy. 
Upon the detection of low ALB concentrations in 
her younger brother, we checked her ALB concen-
tration, which was 10 g/L. However, she showed 
only mild periorbital oedema and had no need for 
ALB infusion. Capillary electrophoresis of serum 
proteins showed the presence of minimal ALB 
concentration associated with a compensatory in-
crease in the non-albumin fractions (Figure 2). Her 
Figure 1. Family pedigree. 
The analbuminemic patients are represented by black symbols 
and are indicated by the arrows. Grey symbols denote hetero-
zygous subjects. Circles symbolize females and squares males. 







Figure 2. Capillary electrophoresis of serum proteins. 
The profiles were obtained via the fully-automated Helena V8 
Capillary Electrophoresis System. A: patient 1; B: control. The 
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developmental milestones are mildly delayed. She 
walked at 1.5 years old, and she still talks with a 
few words. Her growth is also retarded, her weight 
is at 10th centiles and her height is between 3rd 
and 10th centiles.
Sibling 2: The second affected subject is the male, 
last child of the family, who is now one-year-old 
(sibling 2 in Figure 1). Due to foetal distress, he was 
born at 32nd week of gestation following a spon-
taneous conception. His birth weight was 1550 g 
and he stayed in the NICU for 22 days due to pre-
mature birth and respiratory distress. During his 
hospitalization in NICU, he showed low ALB con-
centration (8 - 9 g/L), mild generalised oedema 
and lymphedema of the back of the feet. He re-
ceived ALB infusions. After detailed tests, no gas-
trointestinal or renal loss of protein was detected. 
His hepatic and renal functional tests were normal. 
During follow-up his weight and height stayed be-
low 3rd centiles and his developmental milestones 
were mildly delayed. He had hypotonia and his 
head control was achieved after the 3rd month of 
life. He has not walked yet at 1st year of age. In con-
trast to his affected sister, this boy experienced re-
current upper and lower respiratory tract infec-
tions and he received ALB infusions during his 
stays in the hospital. The more recent visit shows 
that he has neuromotor retardation, severe senso-
rineural hearing loss, and cannot sit without assis-
tance yet. 
Analyte (Unit) Patient 1* Patient 2* Father* Mother*
Albumin (g/L) 10 (38–54) 16 (38–54) 40 (39–49) 41 (39–49)
Total protein (g/L) 50 (60–80) 49 (51 -73) 70 (64–83) 76 (64–83)
Albumin (relative) (%)# 0 .68 (54–70) 17 .17 (54–70) 56.55 (54–70) 48 .39 (54–70)
α1-globulins (relative) (%)# 13 .78 (2- 5) 9 .34 (2 -5) 4.62 (2–5) 4.99 (2–5)
α2-globulins (relative) (%)# 35 .55 (4–11) 37 .89 (4–11) 10.62 (4–11) 10.73 (4–11)
β1-globulins (relative) (%)# 23 .49 (5 -10) 17 .27 (5–10) 9.34 (5–10) 10 .29 (5–10)
β2-globulins (relative) (%)# 5.25 (2–8) 3.02 (2–8) 2.47 (2–8) 5.85 (2–8)
γ-globulins (relative) (%)# 21 .26 (9–19) 15.31 (9–19) 16.4 (9–19) 19 .75 (9–19)
Apolipoprotein B (g/L) 1 .77 (0.60–1.17) 2 .34 (0.66–1.33) 1.05 (0.66–1.33) 1.12 (0.60–1.17)
Apolipoprotein A-1 (g/L) 1.58 (1.08–2.25) 1.34 (1.04–2.02) 1.44 (1.04–2.02) 1.76 (1.08–2.25)
Total cholesterol (mmol/L) 12 .74 (2.79–4.99)  9 .38 (1.96–4.73) 4.99 (2.33 -5.17) 5 .68 (2.33 -5.17)
LDL-cholesterol (mmol/L) 9 .22 (< 2.58) 6 .80 (< 2.58) 3 .05 (< 2.58) 2 .64 (< 2.58)
HDL-cholesterol (mmol/L) 1.55 (1.03–1.55) 1.14 (1.03–1.55) 1.34 (1.03–1.55) 1.42 (1.03–1.55)
Triglycerides (mmol/L) 4 .28 (< 1.69) 3 .14 (< 1.69) 1.31 (< 1.69) 3 .55 (< 1.69)
Calcium (mmol/L 2 .12 (2.2–2.7) 2 .23 (2.25–2.75) 2.38 (2.15–2.5) 2.33 (2.15–2.5)
Phosphate (mmol/L 1.84 (1.00–1.94) 1.81 (1.13–2.13) 1.04 (1.03–1.45) 1.36 (1.03–1.45)
IgA (g/L) 0 .99 (0.16–0.98) 0.61 (< 0.81) 1.90 (0.70–4.00) 2.27 (0.70–4.00)
IgM (g/L) 1 .52 (< 1.22) 1.19 (< 1.22) 0.70 (0.40–2.30) 1.27 (0.40–2.30)
IgG (g/L)) 10 .02 (4.42–8.95) 12 .60 (4.42–8.95) 12.05 (7.00–16.00) 16 .88 (7.00–16.00)
Transferrin (g/L) 7 .51 (2.03–3.60) 6 .46 (2.03–3.60 3 .83 (2.00–3.60) 4 .15 (2.00–3.60)
Lactate dehydrogenase (U/L 37 °C) 725 (< 344) 473 (< 451) 198 (< 480) 204 (< 480)
*Normal values for corresponding age and sex are presented in parenthesis. Values out of the normal reference range are highlighted 
in bold. 
#Serum globulin and albumin fractions were detected after automated capillary electrophoresis, which reported their relative values.
Table 1. Clinical laboratory test results of the analbuminemic patients and of their parents.
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The main recent clinical chemistry data of the 2 
probands and of their parents are summarized in 
Table 1. Both siblings show low ALB concentration 
and low total protein concentration, despite a 
compensatory increment of all the globulin frac-
tions, and gross hyperlipidaemia, with a marked 
increment of total and LDL-cholesterol and hyper-
triglyceridemia. Their total calcium concentrations 
are both close to the lower limit of the normal 
range due to absence of or low binding of calcium 
by ALB.
The other members of the family, the parents (Ta-
ble 1) and the other 2 children, were tested for 
ALB, blood lipids, protein fractions and immuno-
globulin levels. All had ALB concentrations near 
the lower limits of the normal range (39 - 41 g/L), 
suggesting possible carrier status for the CAA trait. 
Mutation analysis 
The screening for mutations of the ALB from the 
DNA of the subjects of this study was carried out 
as previously reported (8,11,20), in order to confirm 
the clinical diagnosis of CAA. SSCP analysis al-
lowed us to locate the causative mutation in the 
309 bp fragment encompassing exon 5 and the 
adjacent intron–exon junctions amplified by using 
PCR primers A09A and A10A (Figure 3). Both the 
homozygous sample (Figure 3, lanes 1, 2 and 1’, 2’) 
revealed the altered conformations of mutated se-
quences resulting in mobility shifted bands when 
compared with controls (Figure 3, lanes 5, 6, 5’, and 
6’). The pattern of the heterozygous parents shows 
the presence of bands corresponding to those 
present in the homozygotes and in the controls 
(Figure 3, lanes 3, 4, 3’, and 4’). The amplified frag-
ment was submitted to automated sequence anal-
ysis as described (8). The results showed that both 
probands are homozygous for the deletion of a 
cytosine residue in a stretch of four cytosines start-
ing from nucleotide position 524 and ending at 
position 527 (NM_000477.5(ALB):c.527delC). (Fig-
ure 4). Both parents were carrier of the mutation 
(data not shown). The results of the analysis re-
vealed the genetic origin of CAA, that is caused by 
a novel single base deletion in the ALB, for which 
we propose the name Erzurum from the city of ori-
gin of the family. The putative effect of the dele-
Figure 3. SSCP analysis of exon 5 from the members of the 
Turkish family. 
The DNA encompassing exon 5 and the exon–intron junction 
was amplified with primers A09A and A10A and the fragments 
were electrophoresed onto a non-denaturing polyacrylamide 
gel: lane 1, patient 1; lane 2, patient 2; lane 3, father; lane 4, 
mother; lanes 5–6, controls. 
The same samples were denatured and cooled before loading: 
lane 1’, patient 1; lane 2’, patient 2; lane 3’, father; lane 4’, moth-
er; lanes 5’–6’, controls. 
The pattern of the homozygous probands revealed the pres-
ence of altered conformations of mutated sequences resulting 
in mobility shifted bands when compared to controls. In the 
heterozygous parents are present the bands which characterise 
both the homozygotes and the controls. Denaturation increas-
es the amount of single-strand PCR products allowing a better 
detection of the bands. 
Figure 4. Genomic DNA sequence electropherograms of pa-
tient 2 (A) and of a control (B). 
The region of the mutation is highlighted in yellow. The pro-
band is homozygous for the deletion of a cytosine residue in a 
stretch of four cytosines starting from nucleotide position 524 
and ending at position 527. 
A
B
tion at the DNA and at the protein level is summa-
rized in Figure 5. The sequence of four cytosines in 
which the deleted base is located includes the last 
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Figure 5. Molecular effect of the cytosine deletion on the DNA and amino acid sequence of the Erzurum allele. 
The numbering above the line refers to the amino acid residue in the ALB precursor. The mutation (c.524_527delC) would cause 
a frame-shift, which changes the codon for Pro 176 to Arg, leading to a premature stop codon TGA at position 240, 65 amino acid 
residues downstream (p.Pro176Argfs*65). The predicted translation product from the Erzurum allele would consist of 215 amino acid 
residues instead of the 585 found in the mature protein.
2 nucleotides in the codon for Ala175 and the first 
2 bases in the codon for Pro176, respectively, in 
exon 5. The subsequent frame-shift changes the 
codon for Pro 176 to Arg, leading to a premature 
stop codon TGA at position 240, 65 amino acid res-
idues downstream, near the 5’ end of exon 7 
(p.Pro176Argfs*65) (Figure 5). Therefore, the pre-
dicted translation product from the Erzurum allele 
would be only 215 amino acids long. This trunca-
tion would cause the lack of domain II and III of the 
mature protein, giving rise to a totally variant se-
quence of 64 amino acids at its C-terminal end, 
particularly rich in basic residues (Figure 5), which 
represents the longest aberrant sequence so far 
hypothesized in a putative product of a mutation 
resulting in CAA. 
Discussion
In the past years, most cases of CAA were diag-
nosed only in adulthood, because of misdiagnosis 
or delayed diagnosis of the condition (4). Recently, 
a more detailed knowledge of the trait allows an 
earlier diagnosis, often in the paediatric age group 
(21-23), as for the Erzurum mutation. Pre-term 
birth, low birth weight, respiratory distress with 
hospital admissions and mild developmental de-
lay are present in the two analbuminemic siblings. 
This adds supporting evidence to the hypothesis 
that the lack of the protein may be a risk factor in 
the perinatal and childhood period (3,5,6). 
The Erzurum frame-shift/deletion is the twenty-
fourth different mutation identified as a cause of 
                   173                           180                                        190 
                    F   Y    A   P    E   L   L   F    F   A   K    R   Y   K   A    A   F   T    
ALB                                   TTT  TAT  GCC  CCG  GAA  CTC  CTT  TTC  TTT  GCT  AAA  AGG  TAT  AAA  GCT  GCT  TTT  ACA 
 
 
                                                                   
                   F   Y   A    R   N    S   F   S   L    L   K   G   I    K   L    L   L   Q 
Putative Erzurum ALB      TTT  TAT  GCC  CGG  AAC  TCC  TTT  TCT  TTG  CTA  AAA  GGT  ATA  AAG  CTG  CTT  TTA  CAG 
 
                                                                                               200              
                                            E   C   C   Q    A    A   D   K    A   A   C   L   L    P   K   L   D    E 
ALB                                  GAA TGT  TGC  CAA   GCT  GCT  GAT AAA  GCT GCC TGC  CTG  TGT  CAA  AAG  CTC GAT  GAA    
                                                                                                                                                               EXON 5     EXON 6 
                                                                        
                    N    V   A   K   L    L   I   K    L   P   A   C   C    Q   S    S   M   N 
Putative Erzurum ALB      AAT  GTT GCC  AAG  CTG  CTG  ATA  AAG  CTG CCT GCC  TGT  TGC  CAA  AGC  TCG ATG  AAC 
 
                                                    210                                                        220               
                                           L    R   D   E   G   K   A    S   S    A   K   Q    R   L   K    C   A   S 
ALB                                  CTT  CGG GAT GAA  GGG AAG GCT  TCG  TCT  GCC  AAA  CAG  AGA  CTC  AAG  TGT GCC AGT 
   
                                                                                 
                     F   G   M   K    G   R    L  R    L   P   N   R    D   S   S    V   P   V 
 Putative Erzurum ALB     TTC GGG  ATG AAG  GGA AGG  CTT CGT  CTG CCA AAC  AGA   GAC  TCA AGT  GTG CCA  GTC  
 
                               230                                                         240              
                                           L   Q   K   F    G   E    R   A   F   K    A  W    A    V   A   R   L   S 
ALB                                  CTC CAA  AAA  TTT  GGA GAA   AGA GCT  TTC  AAA  GCA TGG  GCA  GTA GCT CCG  CTG AGC 
                                                                                                                             EXON 6      EXON 7 
                                                 
                    S   K   N   L   E    K   E   L   S    K   H   G    Q   * 
 Putative Erzurum ALB    TCC AAA  AAT  TTG  GAG  AAA GAG CTT  TCA  AAG  CAT  GGG  CAG  TAG         
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CAA (5,15,23,24). Twenty-two among them cause 
the analbuminemic trait in the homozygous state: 
six nonsense mutations, eight mutations affecting 
splicing, six frame-shift/deletions, one frame-shift/
insertion and one mutation in the start codon 
(5,15, 23,24). Compound heterozygosity for the re-
maining two molecular defects, a nonsense muta-
tion and a splice site mutation with subsequent 
reading frame-shift, caused the trait in an Italian 
man (5,15). Although the variant mRNA could be 
identified in some cases (5), the putative proteins 
produced as a consequence of the 23 mutations 
could never be found in the serum of the affected 
individuals (5,15). The length of the abnormal poly-
peptide chains would range from 31 (Codogno, p.
Gln56*) to 532 (Locust Valley, p.Ile537Asnfs*21) 
amino acids (5,15). The largely aberrant and trun-
cated molecule predicted as the product of the Er-
zurum mutation would be only 215 amino acids 
long, with a theoretical pI and Mw of 8.28 and 
27553.75, respectively, instead of 5.67 and 66472.21 
of the mature ALB. Due to the age of the probands, 
we could not get sera to perform two-dimensional 
electrophoresis, but, on the basis of the above 
mentioned results, it is likely that the Erzurum vari-
ant is also not present in blood. Responsible for 
this absence may be the partial or complete lack in 
all these putative translation products of domain 
III, which plays a crucial role in the ALB binding to 
the intracellular receptor FcRn (25). This receptor 
mediates ALB rescue from lysosomal degradation, 
acting in a pH-dependent way to recycle the pro-
tein back to the blood (25). An alternative explana-
tion is that all the truncated transcripts could un-
dergo nonsense-mediated RNA decay with no 
protein produced (26), since all these mutations 
occur at least 55 bp upstream of the exon13-in-
tron13 boundary. 
The twenty-four mutations identified as cause of 
CAA are located in nine different exons (1, 3, 4, 5, 7, 
8, 10, 11, and 12) and in six different introns (1, 3, 6, 
10, 11, and 12) (5,15, 23,24). This scattered distribu-
tion throughout the gene seems to suggest that 
CAA is the result of randomly occurring deleteri-
ous mutations (27). However, whereas the Erzurum 
mutation, as most of the other causative defects, is 
until now unique, the two bases deletion 
c.228_229delAT (analbuminemia Kayseri) (28) is by 
far the most common cause of the trait, occurring 
in unrelated individuals in different populations 
and accounting for about one-third of the cases 
characterized at the molecular level (5,15,24). 
Therefore, the sequence c.228–c.230 of exon 3, in 
which also the mutation of analbuminemia 
Amasya (c.229_230 delTG) is located (10), seems to 
represent the main hypermutable region in the 
ALB (5,15). 
In conclusion, the molecular analysis, performed 
following our strategy, confirmed the clinical diag-
nosis of CAA in this family, and revealed that the 
condition is due to a novel deletion producing a 
frame/shift defect. The results confirm the inherit-
ance of the trait, and contribute to advance our 
understanding of the molecular basis underlying 
CAA.
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